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Abstract: Degradable bone graft substitute for large-volume bone defects is a continuously
developing field in orthopedics. With the advance in biomaterial in past decades, a wide range
of new materials has been investigated for their potential in this application. When compared to
common biopolymers within the field such as PLA or PCL, elastomers such as polyurethane offer
some unique advantages in terms of flexibility. In cases of bone defect treatments, a flexible soft filler
can help to establish an intimate contact with surrounding bones to provide a stable bone-material
interface for cell proliferation and ingrowth of tissue. In this study, a porous filler based on segmented
polyurethane incorporated with poly L-lactic acid was synthesized by a phase inverse salt leaching
method. The filler was put through in vitro and in vivo tests to evaluate its potential in acting as
a bone graft substitute for critical-sized bone defects. In vitro results indicated there was a major
improvement in biological response, including cell attachment, proliferation and alkaline phosphatase
expression for osteoblast-like cells when seeded on the composite material compared to unmodified
polyurethane. In vivo evaluation on a critical-sized defect model of New Zealand White (NZW)
rabbit indicated there was bone ingrowth along the defect area with the introduction of the new filler.
A tight interface formed between bone and filler, with osteogenic cells proliferating on the surface.
The result suggested polyurethane/poly L-lactic acid composite is a material with the potential to act
as a bone graft substitute for orthopedics application.
Keywords: biomaterial; bone graft substitute; bone filler
1. Introduction
In clinical terms, a critical-sized bone defect is defined as, “The smallest size tissue defect that
will not completely heal over a natural lifetime” [1]. Natural healing of these defects is usually
limited by their large involved volume, which prohibits cell proliferation and signal transmission [2].
The formation of these critical defects can be caused by external factors such as a physical fracture,
or a pathological disorder such as trauma or malignancy [3]. Direct consequences include pain and
anatomical deformation and, in some cases, significant long-term morbidity. In most of the clinical
cases, trauma is considered as the major cause of large-volume permanent bone loss, which leads to
non-union and structural failure in the skeletal system of the patient [4]. How to promote healing
and osteogenesis inside these defects has been a common topic within clinical sectors for the past
40 years. Traditional vascularized autogenic bone grafting has served as the gold standard treatment
for promoting regeneration in general bone defects. A limited supply and donor-site morbidity
of autogenic bone grafts, however, have created obstacles in many clinical cases, especially when
large-volume defects are involved [5–9]. For the past decade, with the advance in tissue regeneration
therapies, many novel techniques had been developed for promoting healing in critical-sized bone
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defects [8,10–22]. Examples of new treatments under development include intramedullary lengthening
devices, bioactive membranes, osteogenic proteins and tissue engineering [8,22–30].
One promising new technique for promoting healing in these large-volume defects is bone-graft
substitutes. A bone-graft substitute, in general, is an artificially introduced filler that provides an
anchoring point for cell proliferation and temporary structural support for tissue ingrowth, which
in the meantime can be integrated into, or completely replaced by, newly formed tissue after the
healing process is complete [31,32]. Traditionally, ceramic is the most favorable material as a bone-graft
substitute because of its great osteoconductivity and osteoinductivity. Various kinds of hydroxyapatite
and TCP-based fillers are undergoing investigation and clinical trial for their potential in facilitating
bone healing [8,9,32–34]. On the other hand, developments in biomaterial have opened up new material
choices within this field. Polymers are a new material family that has appeared on the list of artificial
bone-graft substitutes [24,35–37]. When compared to traditional high-strength fillers such as ceramics
and metals, polymers offer advantages in biodegradability and flexibility [35,38]. A great advantage of
polymer filler over metal and ceramics is that it can be used to fill a larger variety of defects of different
sizes and shapes thanks to its ease of fabrication. Many different types of polymer have undergone
investigation for their potential in regeneration medicine applied to orthopedics [12,35]. Some common
candidates such as poly-L-lactic acid and poly-L-glycolic acid have shown high compatibility with
living tissue and can induce a significant effect on osteoconduction [39–43].
In our study, a new polyurethane composite is investigated for its potential as a filler in
critical-sized bone defects. Polyurethane has a long history within in vivo application, such as artificial
heart valves [44–47]. It is a non-toxic material that induces little or no negative effects in a living
body [48–51]. However, compared to the traditional polymers mentioned above, polyurethane is
a less popular material for regeneration medicine. Despite possessing unique physical properties
favorable for some clinical applications [44,52–55], a few setbacks have concealed the full potential of
polyurethane as a degradable filler. Polyurethane is a degradable polymer in vivo but is subject to a
slow degradable rate that can last for a long time after implantation [56,57]. The hydrophobicity and
bio-inertness of polyurethane also results in a low cell adhesion coefficient when compared to other
biopolymers, which can affect the proliferation of cells [58].
Nevertheless, polyurethane has a soft nature that is unique among synthetic biopolymers.
A polyurethane scaffold can be deformed under external stress without losing integrity and is able to
restore its dimensions after deformation. This is not only convenient during implantation surgery, but
also allows better localization inside the desired area during the healing process, especially in an area
that involves active movement and constantly changing external stress. The soft texture also enables
the material to tightly fill the defects and establish a stable interface with surrounding tissue, which
is beneficial for new tissue formation [59]. The integrity of polyurethane when subjected to external
stress also offers a structurally stable environment for tissue growth. These unique properties offer
polyurethane an advantage over the majority of stiff and brittle biopolymers when acting as a tissue
filler in large-volume defects [50,59].
In this study, the potential of polyurethane-based material as a bone filler for osteogenesis in
critical-sized defects is evaluated. To counter the shortcomings of polyurethane, poly L-lactic acid was
incorporated to improve tissue responses including cell compatibility and in vivo degradation rate [60].
It was hypothesized that the improvement in biological response could lead to improvement in
osteoconductivity and osteoinductivity of the polyurethane scaffold. In vitro and in vivo investigation
were conducted to evaluate the potential of the new bone filler in orthopedic applications.
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2. Material and Methods
2.1. Fabrication of Polyurethane/Poly L-Lactic Acid Filler
S Segmented polyurethane [61] with average molecular weight 1 × 105 was dissolved in 99%
N,N-Dimethylformamide (Sigma Aldrich, St. Louis, MO, USA, cat no. #D158550-4L) at 80 ◦C with
continuous stirring for 24 h to form a polyurethane solution of 9.5% w/v. Undissolved raw polymer
was removed by suction filtration with a glass filter. An 8% w/v poly-L-lactic solution was prepared by
dissolving poly-L-lactic granules (Goodfellow Cambridge, Huntingdon, UK, LS399664) into chloroform
(Merck, Kenilworth, NJ, USA, 1.02455.2500) under vertex. During stirring, the poly-L-lactic acid
solution was added to the polyurethane solution drop by drop. The solution was removed from the
heat source immediately. Sodium chloride in a volume ratio of about 1:1.5 was added slowly to the
composite solution with extensive stirring until the first sight of polymer displacement. The mixture
was allowed to solidify and dry for 7–14 days and was then transferred to a 60 ◦C oven until all the
solvent had evaporated. After solidification, the mixture was under dialysis with deionized water for
48–72 h until all the sodium chloride particles were dissolved and removed from the remaining scaffold.
Five different PL/PU composites with different composition ratios were investigated. The composition
ratio is summed up in Table 1.
Table 1. Weight ratio of different polyurethane composites used in the investigation.
Code Name Weight Ratio, Polyurethane (PU):Poly L-Lactic Acid (PL)
PU 1:0
PL/PU 1:4 1:0.25
PL/PU 1:2 1:0.5
PL/PU 3:4 1:0.75
PL/PU 1:1 1:1
2.2. Culture of Osteoblast and Cell Seeding
7F2 mouse osteoblast obtained from ATCC (ATCC CRL-12557, Manassas, VA, USA) was
subcultured and expanded under general protocol. Prior to cell seeding, the culture medium was
discarded and the monolayer rinsed with 1× sterilized phosphate buffer solution. 0.25% w/v trypsin
was added to the monolayer and culture at 37 ◦C for 5 min until the cell layer was dispersed.
Dispersed cells were diluted to 1 M cell/mL before cell seeding.
Scaffolds were cut into circles 11 mm in diameter and 2 mm in thickness using a sharp blade.
The samples were then packed with double packing and sterilized by autoclave before cell seeding.
Prior to cell seeding, sterilized samples were immersed in 0.5 mL culture medium in a 48-well culture
plate for 72 h to allow perfusion of the medium. All samples were anchored by press fitting inside
wells. 5 × 104 cells per well were seeded on the samples with Dulbecco’s Modified Eagle Medium
(high glucose) supplemented with 10% fetal bovine serum as the growth medium. The culture medium
was renewed every three days.
2.3. Cell Viability Assay
MTT cell proliferation assay was performed directly inside the 48-well culture plates. Before the
test, 5 mg of MTT 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was dissolved in 1 mL
of sterilized phosphate buffer solution to form a 12 mM MTT solution. 1 gm of Sodium dodecyl sulfate
was dissolved in 10 mL of 0.01 M HCl to form SDS solution. Old medium was removed from the
culture plate by suction pump. Samples were washed with 1× phosphate buffer solution to remove
residue medium and 1 mL of flesh medium was added. 100 µL of 12 mM MTT solution was added to
each well. The culture plate was covered in aluminum foil and incubated in darkness at 37 ◦C for 4 h.
After incubation, 1 mL of SDS-HCl solution was added to each well to release the pigment. The plate
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was incubated at 37 ◦C for 18 h inside a humidified incubator (Model 371, Thermo Fisher Scientific,
Waltham, MA, USA). After incubation, the content of each well was mixed using a pipette. 200 uL
content from each well was then transferred to a 96-well transparent culture plate. Absorbance at
570 nm was recorded by Thermo Varioskan microplate reader (Varioskan LUX Multimode Microplate
Reader, Thermo Fisher Scientific, Waltham, MA, USA).
2.4. Alkaline Phosphatase Assay
Standard solution was prepared from 0.1 mg/mL alkaline phosphate control enzyme (Sigma
Aldrich cat no C9361, St. Louis, MO, USA) starting with a 1:100 dilution. A standard curve was
prepared from the diluted standard solution according to the following concentrations: 100%, 50%,
25%, 12.5%, and 6.25%. A substrate solution was prepared by dissolving 1 mg of 4-methylumbelliferyl
phosphate disodium (Sigma Aldrich cat no M8168, St. Louis, MO, USA) in 330 µL of deionized water.
Samples were washed gently with 1× phosphate buffer solution. Cell lysate was prepared by adding
1 mL of cell lysate buffer to each sample. The samples with cell lysate buffer were then placed in
a 4 ◦C refrigerator for 30 min. After the cytolysis, the cell lysate was cooled to room temperature.
20 µL of each sample was transferred to a black 96-well culture plate. To each well, 20 µL of dilution
buffer (Sigma Aldrich cat no B6433, St. Louis, MO, USA) and 160 µL of fluorescent assay buffer (Sigma
Aldrich cat no B6558, St. Louis, MO, USA) were added. Before plate reading, 1 µL of the 10 nM
substrate was adder to each well and mixed. The plate was read under Thermo Varioskan microplate
reader at 360 nm excitation and 440 nm emission.
2.5. Energy Dispersive X-ray Spectroscopy
Collected samples were washed with 1× sterilized PBS to remove all residue medium. Samples
were fixed with 10% for 30 min. After fixation, all samples were dehydrated according to the following
protocol; 70% ethanol (20 min, two changes), 80% ethanol (20 min, two changes), 90% ethanol (30 min,
three changes) and 100% ethanol (30 min, three changes). The samples were dried and stored inside a
desiccator to remove all moisture on the surface before the imaging process. 1 µm-thick gold particle
was coated on the surface of the samples for better electron conductivity.
2.6. In Vivo Evaluation on Artificial Created Critical Sized Defect
A NZW rabbit at 9-week-old and weighing about 2.5 kg was chosen as the subject for in vivo
evaluation. An artificial defect of 20 mm was created on left radius of the animal. (Figure 1)
The operation began by giving the rabbit a preoperative cocktail of antibiotics and sedation, which
included 15 mg/kg subcutaneous cephalexin, intramuscular ketamine (35 mg/kg), Xylazine (5 mg/kg)
and acepromzine (1 mg/kg). Before the surgical operation, procedures such as hair shaving and skin
disinfection were carried out on the surgical site. An incision was created above the distal radius.
Muscle was separated to expose the bone. A segmental defect of 20 mm was created by surgical saw
under constant cooling with saline. After removal of a radius segment, the polyurethane composite
fillers were implanted into the defect by press fitting without any further external or internal support.
After implantation, the wound was closed by simple suture and the forearm was fixed by bandage.
The animal was allowed to recover under normal nursing care with a post-operation treatment of
0.1 mg/kg buprenorphine and 15 mg/kg enrofloxacin for 5 days.
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Figure 1. Critical-sized bone defect created on ulna of NZW rabbits. (a) Surgical sight; (b) Under  
X-ray imaging. 
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Figure 1. Critical-sized bone defect created on ulna of NZW rabbits. (a) Surgical sight; (b) Under
X-ray imaging.
2.7. Tissue Processing after Sacrifice of Animal
At the respective time, the rabbit was sacrificed with an overdose pentobarbital. A large section
of radius including the defect site was harvested and fixed in 10% formalin buffer solution for 1 week
before dehydrate in ethanol (70%, 95%, 100%). After dehydration, the sample was infiltrated with
xylene for 48–96 h and then embedded with MMA. Embedded samples were cut into sections by
an embedded diamond cutting band system complete with precision parallel control contact point
(EXAKT 300CP, Oklahoma City, OK, USA) to a thickness of about 0.3 mm. The sections were attached
on transparent slices by methyl methacrylate precision adhesive (EXAKT 7210 VLC, Oklahoma City,
OK, USA). The sections were polished by micro grinding to a final thickness of about 0.07 mm. Polished
sections were dried for histological staining.
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Figure 2. 7F2 osteoblast cultured on polyurethane composite fillers with different composition under
LIVE/DEAD stain, 3 days after cell seeding.
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Figure 3. (a) Cell viability and; (b) dsDNA level in 7F2 culture on polyurethane composite 3 days after
seeding, measured by MTT cell proliferation assay and pico-green assay respectively (n = 5) (* p > 0.05).
3.1.2. Cell Activities and Proliferation
A higher cell activity level could be detected in culture on all polyurethane composite samples.
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Figure 4. Cell viability level throughout a 21-day culture period of 7F2 cells on polyurethane composites,
measured with MTT cell proliferation assay (n = 5).
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3.1.3. Osteogenic Response
Overall, a higher alkaline phosphatase activity was detected in culture on polyurethane composite
fillers than on unmodified polyurethane. At day 3 of the experiment, at least 2.3 times higher
alkaline phosphatase activity was recorded in collected cell lysate on polyurethane composite than
on unmodified polyurethane fillers (Figure 5). A lower activity was detected in culture on samples
with lower poly L-lactic acid content. The highest activity, which was about 48% of the activity level of
the positive control, was detected in culture on sample PL/PU 1:1. Alkaline phosphatase activity of
culture was in general higher in composite groups throughout the in vitro culture period. At day 14
the activity level for culture on the composite fillers was an at least 35% higher (Figure 6).
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(Figure 8). Most of the calcium appeared as calcium oxide-based crystals located inside the pores of an
extensive extracellular matrix covering the material surface.
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3.1.4. Establishment of a Critical-Sized Bone Defect Model in NZW Rabbit
Prior to the main study, a critical bone defect model was established. From the results obtained
in the prior study, a critical-sized defect can be achieved by removing about 20 mm of bone from the
ulna. There is almost complete recovery for any defect of less than 1.5 mm after 1 year of healing even
without any artificial influences, contrary to the model widely employed in various literatures [62–65].
(Figure 9) This finding can also be confirmed under CT-scanning (Figures 10 and 11).
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3.1.5. In Vivo Evaluation on Artificial Created Critical-Sized Defect
Only PL/PU2:1 was chosen for further animal study because the composition causes little
alternation in physical properties while having a significant positive effect on biological response.
One-year investigation of critical-sized bone defects facilitated with composite polyurethane fillers was
conducted on NZW rabbits. Continuous inspection of the healing process using X-ray images indicated
that there was no, or only slight, dislocation of bones during the healing process. The broken ulna
remained in its original orientation. The early stage of healing shared many similarities with healing in
typical critical-sized defects. One month after the surgical operation, new calcification tissue could be
observed in an area in between the radius and ulna near both ends of the defect. The calcification took
place around the original cortical bone, which forms a callus around the defected ulna. Two months
after the surgical operation, there were traces of remodeling of the ulna and radius in both defect ends,
which eventually caused fusion of the two bones. Fusion of the two bones could be observed 1 month
after the operation. The area was dominated by newly formed irregular calcification and a loss of
original well-defined cortical structure (Figure 12).
Calcification into the defect area could be observed as early as 1 month after the implantation.
The calcification began in the defect ends at the same time with the formation of callus. During the
6-month observation period, a slow ingrowth of this calcified tissue into the defect site could be
observed. Calcified tissue of about 3–5 mm developing from the ulna into the defect area could be
verified with a conventional X-ray 6 months after surgery. Most of these tissues were located in the
interior side, in other words in between the area of implanted filler and the radius. There was a gradual
increase in density and a slow increase in volume of this calcified tissue during the observation period
on the majority of the animal subjects. There was no reunion of the defected ulna after 1 year of
healing. By contrast with results obtained in the unmodified polyurethane implanted group, there was
calcification in a location away from the radius on the implant. This calcified outgrowth originated in
the proximal side of the defect at the ulna, progressing to the distal side, penetrating to about 5–7 mm
into the defect area on some samples. There was a significant increase in length of this outgrowth
throughout the 1-year observation period, but bridging between the defects was not complete by the
end of experimental period (Figure 12).
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were tough and had relatively low elasticity. At the proximal side of the implant there existed 
calcified hard tissue that ran about 1 cm down from the proximal end of the ulna. 
Figure 12. Healing process of critical-sized bone defect in NZW rabbit model with different implants.
After scarification, dissection of the animal revealed extensive formation of new tissue around
the implantation site (Figure 13). The filler had been completely surrounded by these newly formed
tissues, which resemble the anatomy of a normal limb. Despite not being highly calcified, these tissues
were tough and had relatively low elasticity. At the proximal side of the implant there existed calcified
hard tissue that ran about 1 cm down from the proximal end of the ulna.
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Thickening of the cortical bone could be observed near the defect area. Next to the site of implantation 
there was partial loss of cortical structure in the ulna and radius where they were adjacent to each 
other. The ulna and radius fused into one single bone. Under reconstructed cross sections there was 
formation of a new calcified trabecular structure within the cortex. New bone formation was more 
extensive in the proximal end than the distal end of the defect. In a region within 1 cm of the proximal 
end of defect, newly formed calcified tissue expressed a compact cortex with a narrow central region 
which resembled the anatomy of compact bone with medullary cavity. After 1 year of healing, the 
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Thickening of the cortical bone could be observed near the defect area. Next to the site of implantation
there was partial loss of cortical structure in the ulna and radius where they were adjacent to each
other. The ulna and radius fused into one single bone. Under reconstructed cross sections there was
formation of a new calcified trabecular structure within the cortex. New bone formation was more
extensive in the proximal end than the distal end of the defect. In a region within 1 cm of the proximal
end of defect, newly formed calcified tissue expressed a compact cortex with a narrow central region
which resembled the anatomy of compact bone with medullary cavity. After 1 year of healing, the
outgrowth reached 1 cm at the exterior side of the defect (Figure 14).
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Differences in healing response between the composite and unmodified polyurethane filler are
grouped in the following Table 2.
Table 2. Summary of healing response of composite and un-modified polyurethane filler in critical-sized
bone defect.
Healing Response PL/PU Composite Filler Unmodified Polyurethane Filler
Dislocation - -
Necrosis - -
Fibrous tissue inside pore system + +
Cell ingrowth + +
Calcification inside the porous system + -
Bone formation across the defect + -
The presence of calcification was further confirmed under histological staining. Tissue penetration
into the scaffold could be observed inside both the pure and composite scaffold, but with a reduction
of the fibrous capsule between the bone and composite scaffold interface. (Figure 15). Calcification
into the defect area could only be found on the composite group. The bony outgrowth was located on
the surface of the implanted filler rather than inside the pores. There was extensive cell penetration
into the filler structure but most of the volume remained uncalcified. Fibrous tissue dominated the
space inside the porous system. Calcification could be found inside the pores only at the segmental
ends of the ulna and was in close contact with the composite filler. (Figures 16 and 17).
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polyurethane composite filler (Alizarin red, counter stain with Toluidine blue). Osteoblast can be found
next to the newly formed bones inside the porous filler.
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4. Discussion
Recent developments in tissue regeneration medicine have established various new methods
for bone regeneration. Many of these successes relate to the introduction of growth factors, stem cell
therapy, as well as a new artificial matrix for tissue proliferation [8,22–30]. While natural polymers and
ceramics still dominate in the field of bone regeneration, biopolymers such as PLA play an important
role thanks to their flexibility and ease of fabrication [8,12,18]. Compared to many other biopolymers,
the application of polyurethane in regeneration medicine is relatively rare due to its bio-inert nature
and long in vivo degradation time. As a degradable bone filler for orthopedics, polyurethane is usually
considered as lacking the mechanical strength for weight-bearing as well as having a low cell adhesion
coefficient and long degradation time. However, polyurethane offers unique advantages with its
physical properties. Its soft and flexible nature enables it to be fitted into all kinds of defects while
at the same time maintaining close contact with surrounding tissue. Tight fitting can also reduce the
chances of dislocation during healing. Its high elasticity prevents accumulation of stress inside the
defect, minimizing the effect of external stress on the healing process. The toughness and flexibility of
the material under long-term implantation suggests high compatibility with healing processes that
take a long time. These special advantages raise interest in employing polyurethane as a bone filler for
tissue regeneration in critical-sized defects where the weight-bearing issue is less essential. None of
the implanted filler in our experiment suffered from dislocation, and it maintained close contact with
segmented bone throughout the experimental period. There is no doubt this can help in establishing a
more stable interface during the healing process.
To counter the shortcomings of polyurethane, including the bio-inert surface chemistry, long
degradation time and low wettability, poly L-lactic acid was incorporated into polyurethane to form a
composite porous filler. The resulting filler has different mechanical behavior (reduction in elasticity
and strength, increase in resistance to permanent dimension change under stress), but shares the
same favorable soft nature of polyurethane. The biological response of the filler could be significantly
improved with this composition. Initial cell attachment efficiency as well as cellular metabolism under
in vitro culture was significantly improved. There was also an increase in the extracellular matrix
deposition and an increase in the expression of osteogenic markers such as alkaline phosphatases
activity and calcium deposition. It is suggested that the improvement in osteogenic cellular response
was due to the combined effect of surface chemistry modification and an improvement in wettability.
Under fluorescent imaging and a scanning electron microscope, we could observe the increase in poly
L-lactic acid content encouraging more cells to form lamellipodia with the material surface. This led to
the improvement in cell attachment and encouraged seeded cells to express their typical morphology,
which is beneficial for cell metabolism.
When compared to unmodified polyurethane filler, there was an increase in the degradation rate,
which is more compatible with the regeneration rate of bone. The most significant finding in the animal
study was that polyurethane composite filler can promote the formation of calcification bridging across
critical-sized defects. With pure polyurethane filler, calcification and bone regeneration is missing
due to the bio-inertness of polyurethane, which has already been described in related studies [51].
This setback can be significantly overcome by incorporating the poly L-lactic acid. After modification,
calcified tissue can propagate on the new material with osteoblasts penetrating into the porous
system. Intra-matrix calcification could also be confirmed under micro CT-scanning and histological
staining, which suggested the filler can encourage a certain degree of calcification. Formation of these
calcifications around the filler indicated an improvement in osteoconductivity. As with the result of
in vitro tests, this improvement is believed to be due to the improvement in the biological response of
the modified polyurethane composite.
It is not disputed that the result of the in vivo experiment presented here cannot achieve the same
degree of recovery as that found in some of the published literature on similar animal models [25].
The major reason for this is that no osteogenic growth factors and stem cells were introduced in this
study, which significantly reduced the amount of calcification and the healing rate. Various literature
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supports the idea that the introduction of rhBMP can promote calcification and bone regeneration in
large defects [25,66–71]. The introduction of mesenchymal stem cells can also significantly improve
bone formation within these defects [69]. Despite a lesser degree of calcification in our result when
compared with biological incorporated systems, dissection confirmed that there is guided connective
tissue formation across the defect gap that resembled the anatomy of natural bone. The presented
filler is comparable, or can offer an advantage in anatomical reconstruction as well as calcified tissue
formation when compared to some bone graft substituting biopolymers [72–74].
In overall terms, the biological response of polyurethane can be effectively improved by
incorporating poly L-lactic acid, while at the same time retaining the feasible physical properties
of polyurethane. This produces a flexible soft scaffold capable of fitting in most bone defects with a
low chance of dislocation and acceptable osteoconductivity. Investigation on animal models indicated
that the composite filler can facilitate calcification inside artificially created critical-sized defects even
without the introduction of cells and growth factors. The results demonstrate the potential of this
polyurethane composite as a filler material for healing facilitation across critical-sized bone defects.
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